603 related articles for article (PubMed ID: 30301880)
1. Dengue virus and the host innate immune response.
Uno N; Ross TM
Emerg Microbes Infect; 2018 Oct; 7(1):167. PubMed ID: 30301880
[TBL] [Abstract][Full Text] [Related]
2. Innate immunity to dengue virus infection and subversion of antiviral responses.
Green AM; Beatty PR; Hadjilaou A; Harris E
J Mol Biol; 2014 Mar; 426(6):1148-60. PubMed ID: 24316047
[TBL] [Abstract][Full Text] [Related]
3. Innate Antiviral Immunity against Dengue Virus.
Makhluf H; Shresta S
Crit Rev Immunol; 2015; 35(3):253-60. PubMed ID: 26559229
[TBL] [Abstract][Full Text] [Related]
4. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus replication in infected human keratinocytes leads to activation of antiviral innate immune responses.
Surasombatpattana P; Hamel R; Patramool S; Luplertlop N; Thomas F; Desprès P; Briant L; Yssel H; Missé D
Infect Genet Evol; 2011 Oct; 11(7):1664-73. PubMed ID: 21722754
[TBL] [Abstract][Full Text] [Related]
6. Evasion of early innate immune response by 2'-O-methylation of dengue genomic RNA.
Chang DC; Hoang LT; Mohamed Naim AN; Dong H; Schreiber MJ; Hibberd ML; Tan MJA; Shi PY
Virology; 2016 Dec; 499():259-266. PubMed ID: 27716465
[TBL] [Abstract][Full Text] [Related]
7. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
Hadjilaou A; Green AM; Coloma J; Harris E
J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.
Zellweger RM; Tang WW; Eddy WE; King K; Sanchez MC; Shresta S
J Virol; 2015 Jun; 89(12):6494-505. PubMed ID: 25855749
[TBL] [Abstract][Full Text] [Related]
10. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
Gelanew T; Hunsperger E
Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
[TBL] [Abstract][Full Text] [Related]
12. Human C5a Protein Participates in the Mosquito Immune Response Against Dengue Virus.
Londono-Renteria B; Grippin C; Cardenas JC; Troupin A; Colpitts TM
J Med Entomol; 2016 May; 53(3):505-512. PubMed ID: 26843451
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4.
Tamura T; Zhang J; Madan V; Biswas A; Schwoerer MP; Cafiero TR; Heller BL; Wang W; Ploss A
Emerg Microbes Infect; 2022 Dec; 11(1):227-239. PubMed ID: 34931940
[TBL] [Abstract][Full Text] [Related]
14. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans.
Moi ML; Takasaki T; Omatsu T; Nakamura S; Katakai Y; Ami Y; Suzaki Y; Saijo M; Akari H; Kurane I
J Gen Virol; 2014 Mar; 95(Pt 3):591-600. PubMed ID: 24323638
[TBL] [Abstract][Full Text] [Related]
16. A novel mosquito ubiquitin targets viral envelope protein for degradation and reduces virion production during dengue virus infection.
Troupin A; Londono-Renteria B; Conway MJ; Cloherty E; Jameson S; Higgs S; Vanlandingham DL; Fikrig E; Colpitts TM
Biochim Biophys Acta; 2016 Sep; 1860(9):1898-909. PubMed ID: 27241849
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to dengue virus in the skin.
Rathore APS; St John AL
Open Biol; 2018 Aug; 8(8):. PubMed ID: 30135238
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
Katzelnick LC; Montoya M; Gresh L; Balmaseda A; Harris E
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):728-33. PubMed ID: 26729879
[TBL] [Abstract][Full Text] [Related]
19. Approaches to Interrogating the Human Memory B-Cell and Memory-Derived Antibody Repertoire Following Dengue Virus Infection.
Lyski ZL; Messer WB
Front Immunol; 2019; 10():1276. PubMed ID: 31244836
[TBL] [Abstract][Full Text] [Related]
20. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
